- Published on
Infectious Disease and Microbiology – Cervicitis
Cervicitis is a sexually transmitted infection characterized by inflammation of the endocervix and/or ectocervix. It is frequently encountered in sexually active adolescents and young adults, particularly women under 25 years of age.
Cervicitis is common among sexually active adolescent girls under 20 years and young adults aged 20–24 years. In a large U.S. cohort study of individuals aged 18–26 years, the prevalence of chlamydial infection was approximately 4.2%, with higher rates among women than men. Gonorrhea was less common, with a prevalence of 0.4%, and coinfection with both pathogens was rare.
Major risk factors include a new sexual partner within the past 3 months, multiple sexual partners within 6 months, a partner with multiple partners, and inconsistent use of barrier contraception. Preventive strategies emphasize safe sex practices, evaluation and treatment of sexual partners, and annual screening for Chlamydia trachomatis in sexually active women aged 25 years or younger and older women with risk factors. Presumptive treatment is recommended when local prevalence of chlamydia or gonorrhea is high or when follow-up is uncertain.
The most common etiologic agents are Chlamydia trachomatis and Neisseria gonorrhoeae. Other organisms include Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, and herpes simplex virus. In many cases, no pathogen is identified. Vaginal infections such as Trichomonas vaginalis or Candida albicans may extend to involve the ectocervix. Rarely, cytomegalovirus is implicated.
Cervicitis is frequently asymptomatic. When present, symptoms include abnormal vaginal discharge, postcoital bleeding, dysuria, urinary frequency, and dyspareunia. On physical examination, a yellow mucopurulent discharge may be visible in the endocervical canal, and the cervix may be friable and bleed easily on contact.
Diagnostic evaluation includes culture of cervical discharge and nucleic acid amplification testing (NAAT) for C. trachomatis and N. gonorrhoeae, which can be performed on endocervical swabs, vaginal swabs, or urine samples. Gram stain may detect gram-negative intracellular diplococci, which are highly specific for gonococcal infection but less sensitive in cervicitis than in male urethritis. Microscopic examination of vaginal fluid may show leukorrhea (>10 white blood cells per high-power field), which is associated with chlamydial and gonococcal infection. Women with cervicitis should also be evaluated for bacterial vaginosis, trichomoniasis, and pelvic inflammatory disease. If cervical ulcers are present, testing for herpes simplex virus is indicated.
Management includes appropriate treatment of the patient and sexual partners. Patients and partners should abstain from sexual activity until therapy is completed (7 days after single-dose therapy or after completion of a 7-day regimen). In HIV-infected women, treatment reduces cervical viral shedding and transmission risk. In pre-adolescent children, sexually transmitted pathogens warrant evaluation for possible sexual abuse.
Empiric therapy is appropriate when follow-up is uncertain or prevalence of infection is high. For chlamydial infection, first-line treatment includes azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days. For gonococcal infection, ceftriaxone 250 mg intramuscularly as a single dose is recommended. Alternative regimens for chlamydia include ofloxacin, levofloxacin, or erythromycin. For gonorrhea, oral cephalosporins such as cefixime or cefpodoxime may be used, although they may be less effective than ceftriaxone. Fluoroquinolones are not recommended because of increasing resistance.
In pregnancy, azithromycin or amoxicillin is recommended for chlamydial infection. Doxycycline and fluoroquinolones are contraindicated. Gonorrhea in pregnancy is treated with ceftriaxone. Erythromycin formulations may be used as alternatives, though erythromycin estolate is contraindicated due to risk of hepatotoxicity.
Test-of-cure for chlamydia is recommended only when adherence is uncertain, symptoms persist, reinfection is suspected, or in pregnancy. NAAT testing should not be performed within 3 weeks of treatment due to possible false-positive results from nonviable organisms. Routine test-of-cure is not required for uncomplicated gonorrhea treated appropriately unless symptoms persist. Repeat screening within 3–4 months is recommended due to high reinfection rates, especially in adolescents.
Complications of untreated cervicitis include pelvic inflammatory disease, infertility, ectopic pregnancy, chorioamnionitis, premature rupture of membranes, and puerperal infections. Early detection, treatment, and partner management are essential to reduce long-term reproductive morbidity.
Cervicitis is a sexually transmitted infection characterized by inflammation of the endocervix and/or ectocervix. It is frequently encountered in sexually active adolescents and young adults, particularly women under 25 years of age.
Cervicitis is common among sexually active adolescent girls under 20 years and young adults aged 20–24 years. In a large U.S. cohort study of individuals aged 18–26 years, the prevalence of chlamydial infection was approximately 4.2%, with higher rates among women than men. Gonorrhea was less common, with a prevalence of 0.4%, and coinfection with both pathogens was rare.
Major risk factors include a new sexual partner within the past 3 months, multiple sexual partners within 6 months, a partner with multiple partners, and inconsistent use of barrier contraception. Preventive strategies emphasize safe sex practices, evaluation and treatment of sexual partners, and annual screening for Chlamydia trachomatis in sexually active women aged 25 years or younger and older women with risk factors. Presumptive treatment is recommended when local prevalence of chlamydia or gonorrhea is high or when follow-up is uncertain.
The most common etiologic agents are Chlamydia trachomatis and Neisseria gonorrhoeae. Other organisms include Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, and herpes simplex virus. In many cases, no pathogen is identified. Vaginal infections such as Trichomonas vaginalis or Candida albicans may extend to involve the ectocervix. Rarely, cytomegalovirus is implicated.
Cervicitis is frequently asymptomatic. When present, symptoms include abnormal vaginal discharge, postcoital bleeding, dysuria, urinary frequency, and dyspareunia. On physical examination, a yellow mucopurulent discharge may be visible in the endocervical canal, and the cervix may be friable and bleed easily on contact.
Diagnostic evaluation includes culture of cervical discharge and nucleic acid amplification testing (NAAT) for C. trachomatis and N. gonorrhoeae, which can be performed on endocervical swabs, vaginal swabs, or urine samples. Gram stain may detect gram-negative intracellular diplococci, which are highly specific for gonococcal infection but less sensitive in cervicitis than in male urethritis. Microscopic examination of vaginal fluid may show leukorrhea (>10 white blood cells per high-power field), which is associated with chlamydial and gonococcal infection. Women with cervicitis should also be evaluated for bacterial vaginosis, trichomoniasis, and pelvic inflammatory disease. If cervical ulcers are present, testing for herpes simplex virus is indicated.
Management includes appropriate treatment of the patient and sexual partners. Patients and partners should abstain from sexual activity until therapy is completed (7 days after single-dose therapy or after completion of a 7-day regimen). In HIV-infected women, treatment reduces cervical viral shedding and transmission risk. In pre-adolescent children, sexually transmitted pathogens warrant evaluation for possible sexual abuse.
Empiric therapy is appropriate when follow-up is uncertain or prevalence of infection is high. For chlamydial infection, first-line treatment includes azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days. For gonococcal infection, ceftriaxone 250 mg intramuscularly as a single dose is recommended. Alternative regimens for chlamydia include ofloxacin, levofloxacin, or erythromycin. For gonorrhea, oral cephalosporins such as cefixime or cefpodoxime may be used, although they may be less effective than ceftriaxone. Fluoroquinolones are not recommended because of increasing resistance.
In pregnancy, azithromycin or amoxicillin is recommended for chlamydial infection. Doxycycline and fluoroquinolones are contraindicated. Gonorrhea in pregnancy is treated with ceftriaxone. Erythromycin formulations may be used as alternatives, though erythromycin estolate is contraindicated due to risk of hepatotoxicity.
Test-of-cure for chlamydia is recommended only when adherence is uncertain, symptoms persist, reinfection is suspected, or in pregnancy. NAAT testing should not be performed within 3 weeks of treatment due to possible false-positive results from nonviable organisms. Routine test-of-cure is not required for uncomplicated gonorrhea treated appropriately unless symptoms persist. Repeat screening within 3–4 months is recommended due to high reinfection rates, especially in adolescents.
Complications of untreated cervicitis include pelvic inflammatory disease, infertility, ectopic pregnancy, chorioamnionitis, premature rupture of membranes, and puerperal infections. Early detection, treatment, and partner management are essential to reduce long-term reproductive morbidity.
0 Comments
